Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a niche pharmaceutical distributor like Wellgistics Health Inc. (WGRX) navigates FDA regulations, temperature-controlled logistics, and reimbursement rules isn’t easy. Each 10-K packs dense disclosures about specialty-drug margins, while every 8-K details new wholesaler contracts that can reshape revenue overnight. If you have ever wondered, “Why are Wellgistics Health insider trading Form 4 transactions spiking before a new supplier deal?” you are not alone.
Stock Titan solves the puzzle. Our AI reads every Wellgistics Health quarterly earnings report 10-Q filing the moment it hits EDGAR, then delivers plain-English highlights—cash-flow swings, inventory turns, and segment performance—so you can focus on decisions, not decoding. Need real-time alerts? We ping you the second a Wellgistics Health Form 4 insider transactions real-time notice appears. The platform also answers natural questions such as “Are Wellgistics Health SEC filings explained simply anywhere?” or “What does today’s 8-K mean for cold-chain capacity?”
Beyond summaries, you’ll find deep links to every document type investors care about:
- 10-K & 10-Q: Examine logistics network costs with our Wellgistics Health earnings report filing analysis and Wellgistics Health annual report 10-K simplified.
- Forms 4: Track Wellgistics Health executive stock transactions Form 4 to spot confidence shifts.
- DEF 14A: See the Wellgistics Health proxy statement executive compensation breakdown of distribution-team incentives.
- 8-K: Get Wellgistics Health 8-K material events explained—from new warehouse leases to supply interruptions.
Form 4 filing for Clover Health Investments Corp. (CLOV) discloses three transactions by Jamie L. Reynoso, CEO – Medicare Advantage, on July 3 and July 7, 2025.
- Dispositions: 19,789 Class A shares sold on 7/3/25 at a weighted-average price of $2.58; 2,012 shares sold on 7/7/25 at $2.85. Both sales executed under a Rule 10b5-1 plan adopted 3/13/25.
- Withholding for taxes: 8,706 shares automatically withheld on 7/3/25 at $2.56 to satisfy tax obligations upon RSU vesting.
- Post-transaction ownership: Reynoso continues to hold 3,297,821 Class A shares directly.
- The RSU award that triggered the tax withholding vests quarterly through 1/3/27, subject to continued service.
No derivative security activity was reported. The transactions represent roughly 0.66 % of Reynoso’s stated post-filing stake, indicating a modest reduction in ownership.
Schedule 13D filing overview
On 06/30/2025 Atlantis Holding Corp. and Icon Energy Corp.’s Chairwoman & CEO, Ismini Panagiotidi, disclosed beneficial ownership of 7,685,546 common shares of Icon Energy (“ICON”), representing 77.9 % of the outstanding class.
The position consists of (i) 5,000 common shares held directly and (ii) 7,680,546 shares issuable upon conversion of 17,249 Series A Cumulative Convertible Perpetual Preferred Shares. The Series A shares are convertible, in whole (not in part), between 16 Jul 2025 and 15 Jul 2032 at the lower of US $240 or the 5-day VWAP immediately before notice.
The preferred stock was issued under a 11 Jun 2024 exchange whereby ICON acquired Maui Shipping Co.; a further 2,249 Series A shares were issued in-kind for dividends on 30 Jun 2025. Atlantis is incorporated in the Marshall Islands; Ms. Panagiotidi controls Atlantis and Pavimar Shipping, which manages vessels operated by ICON.
The filing states the stake is held for investment purposes and that there are currently no definitive plans for additional transactions affecting ICON’s capital, governance or operations, though regular discussions with management and directors occur.
Key investor takeaways: (1) ICON is effectively insider-controlled, limiting minority influence; (2) up to 7.68 million new shares could be issued after July 2025, creating potential dilution risk; (3) conversion price linkage to VWAP may mitigate extreme pricing but favors the holder if shares trade below US $240.
FAQ
What is the current stock price of Wellgistics Health (WGRX)?
What is the market cap of Wellgistics Health (WGRX)?
What is the core business of Wellgistics Health Inc.?
How does Wellgistics Health Inc. deliver value to independent pharmacies?
What are the key components of its business model?
How does the integrated technology platform work?
What industry challenges does Wellgistics Health Inc. address?
How is Wellgistics Health Inc. positioned in the competitive landscape?
What are the primary services offered by Wellgistics Health Inc.?
How does the company ensure quality and compliance in its operations?
